These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

436 related articles for article (PubMed ID: 26660282)

  • 1. Heart Failure Resulting From Age-Related Cardiac Amyloid Disease Associated With Wild-Type Transthyretin: A Prospective, Observational Cohort Study.
    Connors LH; Sam F; Skinner M; Salinaro F; Sun F; Ruberg FL; Berk JL; Seldin DC
    Circulation; 2016 Jan; 133(3):282-90. PubMed ID: 26660282
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction.
    González-López E; Gallego-Delgado M; Guzzo-Merello G; de Haro-Del Moral FJ; Cobo-Marcos M; Robles C; Bornstein B; Salas C; Lara-Pezzi E; Alonso-Pulpon L; Garcia-Pavia P
    Eur Heart J; 2015 Oct; 36(38):2585-94. PubMed ID: 26224076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natural History of Wild-Type Transthyretin Cardiac Amyloidosis and Risk Stratification Using a Novel Staging System.
    Grogan M; Scott CG; Kyle RA; Zeldenrust SR; Gertz MA; Lin G; Klarich KW; Miller WL; Maleszewski JJ; Dispenzieri A
    J Am Coll Cardiol; 2016 Sep; 68(10):1014-20. PubMed ID: 27585505
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phenotypic profile of Ile68Leu transthyretin amyloidosis: an underdiagnosed cause of heart failure.
    Gagliardi C; Perfetto F; Lorenzini M; Ferlini A; Salvi F; Milandri A; Quarta CC; Taborchi G; Bartolini S; Frusconi S; Martone R; Cinelli MM; Foffi S; Reggiani MLB; Fabbri G; Cataldo P; Cappelli F; Rapezzi C
    Eur J Heart Fail; 2018 Oct; 20(10):1417-1425. PubMed ID: 30070416
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Wild-type transthyretin cardiac amyloidosis is not rare in elderly subjects: the CATCH screening study.
    Aimo A; Vergaro G; Castiglione V; Fabiani I; Barison A; Gentile F; Ferrari Chen YF; Giorgetti A; Genovesi D; Buda G; Franzini M; Piepoli M; Moscardini S; Rapezzi C; Fontana M; Passino C; Emdin M
    Eur J Prev Cardiol; 2024 Aug; 31(11):1410-1417. PubMed ID: 38456769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of Serum Transthyretin as a Prognostic Indicator and Predictor of Outcome in Cardiac Amyloid Disease Associated With Wild-Type Transthyretin.
    Hanson JLS; Arvanitis M; Koch CM; Berk JL; Ruberg FL; Prokaeva T; Connors LH
    Circ Heart Fail; 2018 Feb; 11(2):e004000. PubMed ID: 29449366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Features of atrial fibrillation in wild-type transthyretin cardiac amyloidosis: a systematic review and clinical experience.
    Mints YY; Doros G; Berk JL; Connors LH; Ruberg FL
    ESC Heart Fail; 2018 Oct; 5(5):772-779. PubMed ID: 29916559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes of clinical characteristics, distribution of red flags and prognosis in contemporary patients with wild-type transthyretin amyloidosis cardiomyopathy.
    Sanne Bøjet L; Bertil L; Anders Lehmann Dahl P; Jens Kæstel S; Tor Skibsted C; Steen Hvitfeldt P
    Ann Med; 2024 Dec; 56(1):2398735. PubMed ID: 39247984
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical characteristics and natural history of wild-type transthyretin amyloid cardiomyopathy in Japan.
    Yamada T; Takashio S; Arima Y; Nishi M; Morioka M; Hirakawa K; Hanatani S; Fujisue K; Yamanaga K; Kanazawa H; Sueta D; Araki S; Usuku H; Nakamura T; Suzuki S; Yamamoto E; Ueda M; Kaikita K; Tsujita K
    ESC Heart Fail; 2020 Oct; 7(5):2829-2837. PubMed ID: 32672425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduced trans-mitral A-wave velocity predicts the presence of wild-type transthyretin amyloidosis in elderly patients with left ventricular hypertrophy.
    Yamamura S; Izumiya Y; Ishida T; Onoue Y; Kimura Y; Hanatani S; Araki S; Fujisue K; Sueta D; Kanazawa H; Takashio S; Usuku H; Sugamura K; Sakamoto K; Yamamoto E; Yamamuro M; Yasuda H; Kojima S; Kaikita K; Hokimoto S; Ogawa H; Tsujita K
    Heart Vessels; 2017 Jun; 32(6):708-713. PubMed ID: 27882404
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transthyretin amyloid cardiomyopathy among patients with heart failure and preserved ejection fraction: the AMY score.
    Gioia G; Schrutka L; Jozwiak-Nozdrzykowska J; Kresoja KP; Gunold H; Klingel K; Thiele H; Bonderman D; Lurz P; Rommel KP
    ESC Heart Fail; 2024 Aug; 11(4):2172-2181. PubMed ID: 38613409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of Ventilatory Efficiency Slope as a Marker for Increased Mortality in Wild-Type Transthyretin Cardiac Amyloidosis.
    Yunis A; Doros G; Luptak I; Connors LH; Sam F
    Am J Cardiol; 2019 Jul; 124(1):122-130. PubMed ID: 31053293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Left ventricular structure and function in transthyretin-related versus light-chain cardiac amyloidosis.
    Quarta CC; Solomon SD; Uraizee I; Kruger J; Longhi S; Ferlito M; Gagliardi C; Milandri A; Rapezzi C; Falk RH
    Circulation; 2014 May; 129(18):1840-9. PubMed ID: 24563469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic pathways to wild-type transthyretin amyloid cardiomyopathy: a multicentre network study.
    Tini G; Milani P; Zampieri M; Caponetti AG; Fabris F; Foli A; Argirò A; Mazzoni C; Gagliardi C; Longhi S; Saturi G; Vergaro G; Aimo A; Russo D; Varrà GG; Serenelli M; Fabbri G; De Michieli L; Palmiero G; Ciliberti G; Carigi S; Sessarego E; Mandoli GE; Ricci Lucchi G; Rella V; Monti E; Gardini E; Bartolotti M; Crotti L; Merli E; Mussinelli R; Vianello PF; Cameli M; Marzo F; Guerra F; Limongelli G; Cipriani A; Perlini S; Obici L; Perfetto F; Autore C; Porto I; Rapezzi C; Sinagra G; Merlo M; Musumeci B; Emdin M; Biagini E; Cappelli F; Palladini G; Canepa M
    Eur J Heart Fail; 2023 Jun; 25(6):845-853. PubMed ID: 36907828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Wild-Type Transthyretin Amyloid Cardiomyopathy: A Missed Cause of Heart Failure With Preserved Ejection Fraction With Evolving Treatment Implications.
    Liu PP; Smyth D
    Circulation; 2016 Jan; 133(3):245-7. PubMed ID: 26660283
    [No Abstract]   [Full Text] [Related]  

  • 16. Integrated diagnostic approach to wild-type transthyretin cardiac amyloidosis with the use of high-sensitivity cardiac troponin T measurement and
    Ochi Y; Kubo T; Nakashima Y; Baba Y; Hirota T; Yamasaki N; Yamashita T; Ueda M; Ando Y; Kitaoka H
    J Cardiol; 2020 Jan; 75(1):12-19. PubMed ID: 31324572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myocardial Contraction Fraction by M-Mode Echocardiography Is Superior to Ejection Fraction in Predicting Mortality in Transthyretin Amyloidosis.
    Rubin J; Steidley DE; Carlsson M; Ong ML; Maurer MS
    J Card Fail; 2018 Aug; 24(8):504-511. PubMed ID: 30010028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes After Cardiac Transplant for Wild Type Transthyretin Amyloidosis.
    Rosenbaum AN; AbouEzzeddine OF; Grogan M; Dispenzieri A; Kushwaha S; Clavell A; Daly RC; Edwards BS
    Transplantation; 2018 Nov; 102(11):1909-1913. PubMed ID: 29677073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence and predictors of worsening heart failure in patients with wild-type transthyretin cardiac amyloidosis.
    Ladefoged BT; Dybro A; Dahl Pedersen AL; Rasmussen TB; Vase HØ; Clemmensen TS; Gillmore J; Poulsen SH
    ESC Heart Fail; 2022 Oct; 9(5):2978-2987. PubMed ID: 35733407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The quintessential form of diastolic heart failure in older adults: Wild type transthyretin cardiac amyloidosis.
    Driggin E; Maurer MS
    Clin Cardiol; 2020 Feb; 43(2):171-178. PubMed ID: 31825134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.